Table 3.
Cox proportional hazards regression models for OS and PFS in the entire study population with organ-specific irAEs
Toxicity | OS, Univariable | OS, Multivariable | PFS, Univariable | PFS, Multivariable | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |||||||
Skin toxicity | 0.33 (0.13–0.81) | 0.016 | 0.39 (0.16–0.96) | 0.040 | 0.43 (0.24–0.80) | 0.008 | 0.43 (0.23–0.80) | 0.008 | ||||||
Endocrine toxicity | 0.20 (0.05–0.79) | 0.022 | 0.18 (0.04–0.74) | 0.018 | 0.52 (0.26–1.06) | 0.073 | 0.48 (0.24–0.99) | 0.046 | ||||||
Bone and joint and muscle toxicity | 1.89 (0.60–5.96) | 0.279 | 2.40 (0.74–7.80) | 0.147 | 1.59 (0.59–4.30) | 0.359 | 1.92 (0.70–5.22) | 0.204 | ||||||
Pulmonary toxicity | 0.89 (0.45–1.77) | 0.738 | 0.65 (0.30–1.41) | 0.279 | 1.10 (0.67–1.82) | 0.706 | 0.95 (0.56–1.62) | 0.841 | ||||||
Cardiotoxicity | 0.78 (0.25–2.47) | 0.677 | 0.72 (0.22–2.31) | 0.575 | 0.76 (0.34–1.72) | 0.506 | 0.67 (0.29–1.55) | 0.351 | ||||||
Digestive system toxicity | 0.65 (0.21–2.05) | 0.461 | 0.68 (0.21–2.16) | 0.511 | 0.83 (0.39–1.76) | 0.618 | 0.84 (0.39–1.79) | 0.649 | ||||||
Renal toxicity | 1.88 (0.46–7.63) | 0.379 | 2.50 (0.60-10.42) | 0.208 | 0.83 (0.21–3.34) | 0.790 | 0.99 (0.24–4.04) | 0.987 |
OS: overall survival; PFS: progression-free survival; HR: hazard ratio; irAEs: immune-related adverse events